Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC By Ogkologos - July 14, 2026 192 0 Facebook Twitter Google+ Pinterest WhatsApp Findings after 7 years of follow-up in the CROWN study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Monoclonal Antibodies May Lower Recurrence Risk for Some Early Stage Breast... February 2, 2022 FDA Authorizes Blood Test for Assessing Risk of Hereditary Cancers November 2, 2023 Tailored Radiation to Treat Brain Metastases Reduces Impact on Cognitive Function November 26, 2018 Poziotinib Shows Promising Antitumour Activity in Patients with HER2 Exon 20... September 29, 2021 Load more HOT NEWS Five Questions With…Desiree. FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma FDA Approves Carfilzomib and Daratumumab with Dexamethasone for Multiple Myeloma 17 Old Fashioned Ways to Get Rid of Ants in Your...
